Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745 | 0.86 | RAB9A (0.43) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL5035 | 0.84 | HPGD (0.46) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL1608179 | 0.83 | LPAR1 (0.48) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL10942 | 0.83 | RAB9A (0.46) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL9905 | 0.83 | LPAR1 (0.48) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL1607083 | 0.83 | LPAR1 (0.48) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL9860 | 0.80 | LPAR1 (0.37) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL4792 | 0.80 | RAB9A (0.64) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL9819 | 0.80 | RAB9A (0.56) | RAB9ANPC1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL3776 | 0.80 | BRD4 (0.38) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2014-09-11 | — | — | US | disclosed |
| US-8778983-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2483251-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2483269-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | RAB9A 2536/4885NPC1 339/4885L3MBTL1 2315/4885 |
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | RAB9A 2536/4885NPC1 339/4885L3MBTL1 2315/4885 |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | RAB9A 2536/4885NPC1 339/4885L3MBTL1 2315/4885 |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR4 | RAB9A 2536/4885NPC1 339/4885L3MBTL1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.